Gréta Garami YOU? Author Swipe

Last 10y

Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation Open

Gréta Garami, Omar Obajed Al-Ali, István Virga, Anita Gulyás, Judit Bedekovics , et al. · 2025

Background: A total of 50% of patients with AL amyloidosis have t(11;14) translocation, allowing us to use the selective oral BCL-2 inhibitor venetoclax in their treatment. Case presentation: Our patient was admitted to the gastroenterolog…

Venetoclax Based Induction and Maintenance Therapy for AL Amyloidosis with t(11;14) Translocation Open

Gréta Garami, Omar Obajed Al-Ali, István Virga, Anita Gulyás, Judit Bedekovics , et al. · 2024

Background: 50% of patients in AL amyloidosis have t(11;14) translocation, allowing to use the selective, oral BCL-2 inhibitor venetoclax in their treatment. Case presentation: Our patient was admitted to the Gastroenterology Ambulance due…